newsfilter
← Latest News
GlobeNewswire·

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients